ARTSS-2随机多中心试验:阿加曲班联合rt-PA治疗急性卒中
ARTSS-2是一项随机探索性研究,纳入90例接受标准剂量rt-PA且未行血管内治疗的缺血性卒中患者,比较单用rt-PA与联合阿加曲班(低剂量1 μg/kg/min或高剂量3 μg/kg/min,均先100 μg/kg弹丸注射后输注48小时)的安全性和临床获益概率。结果显示症状性颅内出血率三组相似,联合阿加曲班未增加出血风险,且90天mRS 0-1的概率在联合组更高,提示有必要开展确定性有效性试验。
要点
- 联合阿加曲班未增加症状性颅内出血风险。
- 90天mRS 0-1比例:单用组21%,低剂量组30%,高剂量组32%。
- 阿加曲班优于单用rt-PA的后验概率为67%-79%,支持进一步试验。
核心结论
- 在接受rt-PA治疗的缺血性卒中患者中,联合阿加曲班未增加症状性颅内出血风险,并提示有必要开展确定性有效性试验。
研究设计与样本
- 随机、多中心、探索性研究,纳入90例接受标准剂量rt-PA且未行血管内治疗的患者。
- 患者随机分为单用rt-PA组(29例)、rt-PA+低剂量阿加曲班组(30例)和rt-PA+高剂量阿加曲班组(31例)。
- 阿加曲班给药方案:100 μg/kg弹丸注射后,分别以1 μg/kg/min(低剂量)或3 μg/kg/min(高剂量)输注48小时。
主要发现
- 症状性颅内出血率:单用组3/29(10%),低剂量组4/30(13%),高剂量组2/31(7%)。
- 90天mRS 0-1比例:单用组6例(21%),低剂量组9例(30%),高剂量组10例(32%)。
- 低剂量、高剂量及任一剂量阿加曲班 vs 单用rt-PA达到mRS 0-1的相对风险分别为1.17(95%可信区间0.57-2.37)、1.27(0.63-2.53)和1.34(0.68-2.76)。
- 阿加曲班优于单用rt-PA的后验概率:低剂量67%,高剂量74%,任一剂量79%。
关键数值与推荐
- 安全性主要指标为症状性颅内出血发生率。
- 临床获益概率采用保守贝叶斯泊松模型估计(中性先验概率以相对风险1.0为中心,95%先验区间0.33-3.0)。
临床怎么用
- 对于接受标准剂量rt-PA且未行血管内治疗的缺血性卒中患者,联合阿加曲班可能不增加症状性颅内出血风险。
- 联合阿加曲班可能提高90天良好功能结局(mRS 0-1)的概率,但证据尚不足以改变临床实践,需等待确定性试验。
局限性
- 探索性研究样本量小(共90例),结果需进一步验证。
- 未纳入接受血管内治疗的患者,结论外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: We conducted a randomized exploratory study to assess safety and the probability of a favorable outcome with adjunctive argatroban, a direct thrombin-inhibitor, administered to recombinant tissue-type plasminogen activator (r-tPA)-treated ischemic stroke patients. METHODS: Patients treated with standard-dose r-tPA, not receiving endovascular therapy, were randomized to receive no argatroban or argatroban (100 μg/kg bolus) followed by infusion of either 1 (low dose) or 3 μg/kg per minute (high dose) for 48 hours. Safety was incidence of symptomatic intracerebral hemorrhage. Probability of clinical benefit (modified Rankin Scale score 0-1 at 90 days) was estimated using a conservative Bayesian Poisson model (neutral prior probability centered at relative risk, 1.0 and 95% prior intervals, 0.33-3.0). RESULTS: Ninety patients were randomized: 29 to r-tPA alone, 30 to r-tPA+low-dose argatroban, and 31 to r-tPA+high-dose argatroban. Rates of symptomatic intracerebral hemorrhage were similar among control, low-dose, and high-dose arms: 3/29 (10%), 4/30 (13%), and 2/31 (7%), respectively. At 90 days, 6 (21%) r-tPA alone, 9 (30%) low-dose, and 10 (32%) high-dose patients were with modified Rankin Scale score 0 to 1. The relative risks (95% credible interval) for modified Rankin Scale score 0 to 1 with low, high, and either low or high dose argatroban were 1.17 (0.57-2.37), 1.27 (0.63-2.53), and 1.34 (0.68-2.76), respectively. The probability that adjunctive argatroban was superior to r-tPA alone was 67%, 74%, and 79% for low, high, and low or high dose, respectively. CONCLUSIONS: In patients treated with r-tPA, adjunctive argatroban was not associated with increased risk of symptomatic intracerebral hemorrhage and provides evidence that a definitive effectiveness trial is indicated. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique Identifier: NCT01464788.
引用
- Barreto AD, Ford GA, Shen L, et al. Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke). Stroke. 2017. PMID: 28507269. doi:10.1161/STROKEAHA.117.016720
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。